Abstract
BackgroundIn preclinical studies of pancreatic ductal adenocarcinoma (PDAC), ibrutinib improved the antitumor efficacy of the standard of care chemotherapy. This led to a phase 1b clinical trial to determine the...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have